Vol. 2 No. 8 (2022)
Reimbursement Recommendations

Faricimab (Vabysmo)

Published August 30, 2022

Key Messages

  • CADTH recommends that Vabysmo be reimbursed by public drug plans for the treatment of neovascular (wet) age-related macular degeneration (nAMD) if certain conditions are met.
  • Vabysmo should only be covered to treat patients with nAMD, as per the approved Health Canada indication.
  • Vabysmo should only be reimbursed if prescribed by an ophthalmologist with experience managing nAMD and if the cost per administration is not more than the least costly drug covered by the public drug plans for the treatment of nAMD.